Our News

The extended partnership includes access to Dedalus’s robust data mining technology to facilitate the ingestion, harmonization, and analysis of patient data.

ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces the development of two novel digital instruments to increase accuracy and reduce patient/caregiver burden in pediatric clinical trials.

ObvioHealth and 1nHealth announce today a joint initiative to smooth the transition to hybrid and decentralized clinical research. The initiative focuses on supporting clinical trials that may be struggling due to suboptimal protocol design, imprecise recruitment strategies, maladapted technology options or ailing site teams. According to clinicaltrials.gov, there are about 1,600 suspended trials at present.

ObvioHealth, a leading global Virtual Research Organization (VRO) delivering end-to-end decentralized clinical trial solutions, announces it has completed the first fully virtual urogynecology study in partnership with trial sponsor, Renovia, Inc. The trial validated the efficacy of Renovia’s leva® Pelvic Health System on women’s incontinence, a health concern that affects 62% of U.S. adult women.

Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence. ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.